Praxis Precision Medicines
Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial
Praxis Precision Medicines; vormatrigine; epilepsy; seizures; RADIANT study; focal onset seizures; Phase 2 trial; sodium channel blocker
Praxis touts ‘best-in-disease’ epilepsy data, but shares dip
Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market
Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial
Praxis Precision Medicines, ulixacaltamide, essential tremor, clinical trial failure, stock price drop
Breakthrough in Rare Childhood Epilepsies: Praxis’ Relutrigine Exceeds Efficacy Expectations
Praxis Precision Medicines, relutrigine, rare childhood epilepsies, epilepsy treatment, genetic epilepsy, precision medicine.
Praxis’ Mid-Stage Triumph Propels Advancement of Novel Epilepsy Drug
Praxis Precision Medicines, PRAX-628, Functionally Selective Small Molecule, Hyperexcitable State of Sodium Channels, Adult Focal Onset Epilepsy Treatment, Phase IIa Proof of Concept Study Success, Second Half of 2024 Efficacy Study Planned